Lack Of Interchangeability No Barrier For Amjevita, Says Amgen Executive
Company Expects Product To Receive Designation Some Time After January Launch
While Amgen’s Amjevita (adalimumab-atto) has yet to secure an interchangeability designation, company executives appear confident this will have little impact on their Humira biosimilar’s competitiveness overall.
